PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer

Yunxing Shi, Yi Niu, Yichuan Yuan, Kai Li, Chengrui Zhong, Zhiyu Qiu, Keren Li, Zhu Lin, Zhiwen Yang, Dinglan Zuo, Jiliang Qiu, Wei He, Chenwei Wang, Yadi Liao, Guocan Wang (), Yunfei Yuan () and Binkui Li ()
Additional contact information
Yunxing Shi: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Yi Niu: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Yichuan Yuan: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Kai Li: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Chengrui Zhong: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Zhiyu Qiu: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Keren Li: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Zhu Lin: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Zhiwen Yang: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Dinglan Zuo: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Jiliang Qiu: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Wei He: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Chenwei Wang: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Yadi Liao: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Guocan Wang: The University of Texas MD Anderson Cancer Center
Yunfei Yuan: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine
Binkui Li: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine

Nature Communications, 2023, vol. 14, issue 1, 1-17

Abstract: Abstract Although oxaliplatin-based chemotherapy has been effective in the treatment of hepatocellular carcinoma (HCC), primary or acquired resistance to oxaliplatin remains a major challenge in the clinic. Through functional screening using CRISPR/Cas9 activation library, transcriptomic profiling of clinical samples, and functional validation in vitro and in vivo, we identify PRMT3 as a key driver of oxaliplatin resistance. Mechanistically, PRMT3-mediated oxaliplatin-resistance is in part dependent on the methylation of IGF2BP1 at R452, which is critical for the function of IGF2BP1 in stabilizing the mRNA of HEG1, an effector of PRMT3-IGF2BP1 axis. Also, PRMT3 overexpression may serve as a biomarker for oxaliplatin resistance in HCC patients. Collectively, our study defines the PRTM3-IGF2BP1-HEG1 axis as important regulators and therapeutic targets in oxaliplatin-resistance and suggests the potential to use PRMT3 expression level in pretreatment biopsy as a biomarker for oxaliplatin-resistance in HCC patients.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-37542-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37542-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-37542-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().